Discovering and developing novel therapeutics.
Skip to content
Board of Directors
Scientific Advisory Board
Translational Advisory Board
Awards and Recognition
Betrixaban: FXa Inhibitor
Andexanet alfa: FXa Inhibitor Antidote
Cerdulatinib* (PRT2070): Dual Syk-JAK Inhibitor
PRT2607: Syk-Specific Inhibitor
We are committed to providing the media with timely and accurate information.
FDA Informs Portola Pharmaceuticals at Mid-Cycle Review for Betrixaban That It Has Not Identified Issues that Require an Advisory Committee Meeting
PDUFA Date of June 24, 2017 Under Priority Review SOUTH SAN FRANCISCO, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) has informed the Company, as part of its mid-cycle review, that it does not plan to hold an Advisory Committee meeting for Portola’s New Drug Application (NDA) for betrixaban. Betrixaban is an oral, once-daily Factor Xa inhib...
Portola Pharmaceuticals Signs $150 Million Royalty Agreement with HealthCare Royalty Partners for Development and Commercialization of Andexanet Alfa
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that it has signed a $150 million royalty agreement with HealthCare Royalty Partners (HCR). Under the terms of the agreement, Portola received $50 million at closing and may receive an additional $100 million upon U.S. Food and Drug Administration (FDA) approval of AndexXaTM (andexanet alfa) in exchange for a tiered, mid-single-digit royalty based on worldwide sales of th...
Portola Pharmaceuticals to Webcast Corporate Update on January 10, 2017
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that it will host an investor webcast to review recent achievements and corporate and product milestones over the next year. The webcast, which will take place on Tuesday, January 10, at 7 a.m. Pacific Time (10 a.m. Eastern Time), will coincide with the 35th Annual J.P. Morgan Healthcare Conference in San Francisco. During the investor event, Portola’s senior managemen...